Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVIP in Relapsed/Refractory Lymphoid Malignancies
NCT05371054Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of enitociclib in lymphoid malignancy, non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and 1 more (2 cohorts), sponsored by National Cancer Institute. Primary endpoints: Complete Response Rate at 72 weeks, Number of Solicited and/or Non-solicited Non-serious Adverse Events at 18 weeks and 3 more. Started Apr 2023; status: completed.
02
Drugs
enitociclib
03
Conditions
lymphoid malignancynon-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05371054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371054.